BioMarin’s Roctavian struggles continue. Is a divestment in the future?

Less than a year in­to a rocky roll­out for its gene ther­a­py Roc­ta­vian, Bio­Marin is now talk­ing about whether the prod­uct might be a bet­ter fit out­side the com­pa­ny, and cut­ting sev­er­al pipeline pro­grams.

On Wednes­day, CEO Alexan­der Hardy said that the biotech com­pa­ny is look­ing at plans for the he­mo­phil­ia A treat­ment, which brought in just $800,000 in the first quar­ter. If up­take doesn’t im­prove, Hardy said Bio­Marin may con­sid­er cut­ting the drug from its port­fo­lio al­to­geth­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.